NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,327,860 | -21.3% | 1,822,883 | 0.0% | 1.60% | -14.6% |
| Q2 2023 | $18,210,601 | +112401.4% | 1,822,883 | 0.0% | 1.88% | -7.3% |
| Q1 2023 | $16,187 | -19.1% | 1,822,883 | 0.0% | 2.02% | -9.6% |
| Q4 2022 | $20,015 | -99.9% | 1,822,883 | 0.0% | 2.24% | -21.1% |
| Q3 2022 | $23,752,000 | +2.8% | 1,822,883 | 0.0% | 2.84% | +4.7% |
| Q2 2022 | $23,096,000 | +28.4% | 1,822,883 | +41.9% | 2.71% | +55.0% |
| Q1 2022 | $17,993,000 | -51.6% | 1,284,313 | 0.0% | 1.75% | -40.7% |
| Q4 2021 | $37,181,000 | -3.4% | 1,284,313 | -0.0% | 2.95% | +23.5% |
| Q3 2021 | $38,478,000 | +12.9% | 1,284,314 | 0.0% | 2.39% | +6.9% |
| Q2 2021 | $34,073,000 | -14.7% | 1,284,314 | 0.0% | 2.23% | -1.3% |
| Q1 2021 | $39,929,000 | -5.4% | 1,284,314 | 0.0% | 2.26% | -14.7% |
| Q4 2020 | $42,228,000 | -5.8% | 1,284,314 | 0.0% | 2.65% | -36.6% |
| Q3 2020 | $44,835,000 | – | 1,284,314 | – | 4.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |